TVTX
FDA approves first drug for rare kidney scarring disease
Article Summary
HOLD- Travere Therapeutics (NASDAQ: TREX) received FDA approval for sparsentan to treat focal segmental glomerulosclerosis, a rare kidney disease where filtering units become scarred.
- The drug works by targeting two specific receptors to reduce protein loss through the kidneys, which Travere says helps slow progression of the disease.
- The FDA approved the drug for FSGS after pushing back review timeline, requiring more evidence of clinical benefit.
- Travere licensed the drug from Ligand Pharmaceuticals in 2012, which receives 9% of global revenue and milestone payments under the agreement.
- Competitor Trasentan is now in a mid-stage clinical trial for the same condition.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 110.5% | 25% | 100.0 ptsExceptional (110.5%) - Hypergrowth |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 12.1% | 20% | 50.0 ptsMeets Minimum (12.1%) - Target: $46.64 vs Current: $41.61 |
| Gross Margin % ? | 85.5% | 15% | 100.0 ptsExceptional (85.5%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -1.2% | 15% | 20.0 ptsBarely a Dip (-1.2%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TVTX
- Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
- The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
- Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
- It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.
- Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
- The company is headquartered in San Diego, California.